Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co.

|
Includes: ABAX, ACHV, ACOR, AFFX, ALKS, AMGN, ANIK, BHC, BMRN, CASC, CELG, CLDX, CYTR, ECYT, EXEL, FF, GERN, GEVA, GILD, HAE, HBIO, HSP, INCY, INVA, MACK, MATN, MDXG, MRK, MYL, NBIX, NEO, PCRX, PFE, SESN, SGEN, TEVA, UTHR, VRTX
by: SA Editor Mike Taylor, CFA

Summary

Every week, Seeking Alpha aggregates expected biotech events in an effort to alert readers and contributors to upcoming catalysts.

Crowdsourcing is key, so please let us know about any events we may have missed.

Have a view on something that’s coming up? Submit an article.

Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you think we're missing something, and pitch in ideas to help improve the document.

And now, on to next week's schedule.

Regulatory Events:

April 29:

FDA Ad Comm -- Amgen's T-VEC (talimogene laherparepvec)

April 30:

FDA PDUFA -- Theravance's Breo Ellipta

  • PDUFA goal date for Theravance's (THRX) Breo Ellipta, "a fixed dose combination of the inhaled corticosteroid, fluticasone furoate (NYSE:FF) and the long-acting beta2 agonist (LABA), vilanterol (VI), administered using the ELLIPTA® inhaler" is April 30.

  • Previously: Theravance -10.4% following FDA's Breo Ellipta ruling (March 19)

April 30:

FDA PDUFA -- The Medicines Company's Ionsys

Earnings reports

(Note: Release dates with an asterisk [*] have not been confirmed by company press release.)

Monday, April 27

Before the open:

  • Haemonetics (NYSE:HAE)
  • Merrimack Pharmaceuticals (NASDAQ:MACK)*

After the close:

  • Mylan (NASDAQ:MYL)*

Tuesday, April 28

Before the open:

  • Hospira (NYSE:HSP)
  • Merck (NYSE:MRK)
  • MiMedx (NASDAQ:MDXG)
  • Neogenomics (NASDAQ:NEO)
  • Pfizer (NYSE:PFE)
  • United Therapeutics (NASDAQ:UTHR)

After the close:

  • Anika Therapeutics (NASDAQ:ANIK)
  • OncoGenex Pharmaceuticals (OGXI)*
  • Synageva Biopharma (NASDAQ:GEVA)*

Wednesday, April 29

Before the open:

  • Celldex Therapeutics (NASDAQ:CLDX)*
  • Valeant Pharmaceuticals (VRX)

After the close:

  • Affymetrix (NASDAQ:AFFX)
  • Vertex Pharmaceuticals (NASDAQ:VRTX)

Thursday, April 30

  • OXiGENE (OXGN)

Before the open

  • Acorda Therapeutics (NASDAQ:ACOR)
  • Alkermes (NASDAQ:ALKS)
  • Celgene (NASDAQ:CELG)
  • Eleven Biotherapeutics (EBIO)
  • Harvard Bioscience (NASDAQ:HBIO)
  • Incyte (NASDAQ:INCY)
  • Neurocrine Biosciences (NASDAQ:NBIX)
  • Pacira Pharmaceuticals (NASDAQ:PCRX)
  • Teva Pharmaceuticals (NYSE:TEVA)

After the close

  • Abaxis (NASDAQ:ABAX)
  • Biomarin Pharmaceuticals (NASDAQ:BMRN)
  • Exelixis (NASDAQ:EXEL)
  • Gilead Sciences (NASDAQ:GILD)
  • Seattle Genetics (NASDAQ:SGEN)

A note to readers: Information comes from a variety of sources. Some helpful biotech links include: Twitter search; FDA Ad Comm calendar; Yahoo! Finance; BioPharmCatalyst, and of course Seeking Alpha's healthcare newsand healthcare analysis.

See something here that deserves further analysis? We are always looking for new contributors and submissions in the biotech/healthcare space. You cansubmit an article here to become a contributor. Joining Seeking Alpha's community of writers has substantial benefits:

  • Vet your ideas among Seeking Alpha's community of investors and commentators.

  • Article headlines appear on partner sites, helping to reach a wide audience.

  • Premium articles earn $35 upon publication and $10 per 1,000 page views.

Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it. The author has no business relationship with any company whose stock is mentioned in this article.

Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.